Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416897 | 1.00 | PTPN1 (0.43) | PTPN1HTTRIPK1BCL2A1TDP1 | |
| SCHEMBL6412980 | 0.90 | TDP1 (0.42) | RIPK1BCL2A1TDP1SNCACA12 | |
| SCHEMBL6412983 | 0.90 | TDP1 (0.42) | RIPK1BCL2A1TDP1SNCACA12 | |
| SCHEMBL6411640 | 0.86 | PTPN1 (0.40) | PTPN1HTTRIPK1EGFRERBB2 | |
| SCHEMBL6411635 | 0.86 | PTPN1 (0.40) | PTPN1HTTRIPK1EGFRERBB2 | |
| SCHEMBL6413732 | 0.86 | BCL2A1 (0.53) | PTPN1HTTBCL2A1EGFRERBB2 | |
| SCHEMBL6413735 | 0.86 | BCL2A1 (0.53) | PTPN1HTTBCL2A1EGFRERBB2 | |
| SCHEMBL6415776 | 0.84 | ALDH1A1 (0.47) | BCL2A1TDP1EGFRERBB2SNCA | |
| SCHEMBL6415771 | 0.84 | ALDH1A1 (0.47) | BCL2A1TDP1EGFRERBB2SNCA | |
| SCHEMBL6421244 | 0.84 | SNCA (0.42) | RIPK1TDP1EGFRERBB2SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | PTPN1 3176/4885HTT 1420/4885RIPK1 3528/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | PTPN1 2115/4885HTT 2477/4885RIPK1 3530/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | PTPN1 2115/4885HTT 2477/4885RIPK1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.